Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer

AUAUniversity

English - December 29, 2023 06:30 - 34 minutes - 31.1 MB - ★★★★★ - 32 ratings
Courses Education Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: The Latest Breakthroughs in Immunotherapy for GU Cancers

Next Episode: AUA2023 John K. Lattimer Lecture

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:
Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer

CME Available: https://auau.auanet.org/node/39542
Release Date: December, 2023
Expiration Date: December, 2024

LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Identify the rationale behind using adjuvant therapies in high-risk non-metastatic kidney cancer and the goals of adjuvant treatment.
2. Describe the adjuvant therapies that have been investigated to date for high-risk non-metastatic kidney cancer, including targeted therapies, immunotherapies, and combination approaches.
3. Discuss the challenges and limitations associated with adjuvant therapy trials in high-risk non-metastatic kidney cancer, such as patient selection, trial design, and long-term follow-up.

ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lantheus Medical Imaging
Merck & Co., Inc.